Company intelligence / Profile preview

Abiomed

Danvers, Massachusetts, United States

Ownership: Private
Employees: ~700
Development stage: Other

Overview

Abiomed's Impella platform is the first and only percutaneous ventricular assist device to receive multiple FDA approvals for supporting patients in cardiogenic shock and high-risk percutaneous coronary intervention. Major clinical trials demonstrate improved survival and heart recovery rates. Over 350,000 patients globally have been treated with Abiomed technologies, and all post-approval studies have been completed successfully.[3][5][6][8]

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

Texas Heart Institute (historical, AbioCor development)MedTechVets (co-founder)

Beyond the preview

Go deeper on Abiomed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abiomed.

Explore the full profile